INT178191

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 2004
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 7
Total Number 7
Disease Relevance 4.11
Pain Relevance 0.24

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Erbb2) plasma membrane (Erbb2) nucleus (Erbb2)
kinase activity (Erbb2) cytoplasm (Erbb2)
Anatomy Link Frequency
A549 1
BT-474 1
Erbb2 (Mus musculus)
Pain Link Frequency Relevance Heat
Central nervous system 85 97.12 Very High Very High Very High
methotrexate 15 87.12 High High
palliative 3 31.68 Quite Low
imagery 23 11.68 Low Low
positron emission tomography 10 5.00 Very Low Very Low Very Low
agonist 9 5.00 Very Low Very Low Very Low
cytokine 8 5.00 Very Low Very Low Very Low
isoflurane 5 5.00 Very Low Very Low Very Low
tolerance 4 5.00 Very Low Very Low Very Low
anesthesia 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 462 99.80 Very High Very High Very High
Lung Cancer 30 99.64 Very High Very High Very High
Solid Tumor 32 99.42 Very High Very High Very High
Disease Progression 11 99.32 Very High Very High Very High
Death 11 98.40 Very High Very High Very High
Apoptosis 30 97.24 Very High Very High Very High
Breast Cancer 62 96.12 Very High Very High Very High
Recurrence 37 92.28 High High
Metastasis 61 88.72 High High
Colon Cancer 4 86.56 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Solid tumor and cell line expression of keratins, TP53 and HER2
Regulation (keratins) of HER2 associated with solid tumor
1) Confidence 0.36 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2467432 Disease Relevance 0.86 Pain Relevance 0
The FISH test was performed on routinely processed, formalin-fixed, paraffin-embedded tissues using PathVision Her-2 DNA Probe Kit (Vysis Inc, Doweners Grove I11, and Inform HER-2 Gene Detection System, Ventana Medical Systems, Inc, Tucson, Arizona)
Regulation (using) of Her-2
2) Confidence 0.35 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1579231 Disease Relevance 0.12 Pain Relevance 0.04
The predictive value of the HER2/neu status already reported [8,9] was further confirmed in the present study.
Regulation (value) of HER2/neu
3) Confidence 0.27 Published 2006 Journal Breast Cancer Res Section Body Doc Link PMC1779464 Disease Relevance 1.58 Pain Relevance 0.20
The ability of 89Zr-DFO-trastuzumab to target HER2/neu receptors in vivo was initially assessed by conducting acute biodistribution studies in BT-474 tumor-bearing mice at 1, 12, 24, 48, 72 and 120 h post-i.v. administration (Tables 1 and S1, and Figure 3).
Regulation (target) of HER2/neu in BT-474 associated with cancer
4) Confidence 0.27 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2810330 Disease Relevance 0.43 Pain Relevance 0
Expression levels of HER2/neu were modulated during the first 24 and 48 h post-administration (29.75±4.43%ID/g and 41.42±3.64%ID/g, respectively).
Regulation (modulated) of HER2/neu
5) Confidence 0.27 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2810330 Disease Relevance 0.19 Pain Relevance 0
Alteration of the EGFR/HER-2 receptors and downstream signaling cascades by lapatinib results in apoptosis induction in A549 cells
Regulation (Alteration) of HER-2 in A549 associated with apoptosis
6) Confidence 0.24 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2883966 Disease Relevance 0.45 Pain Relevance 0
Rolf Kiessling (Karolinska Institute, Stockholm, Sweden) opened the Colloquium delivering the keynote lecture about: "The Her-2/neu gene as a target for tumor vaccination".
Regulation (target) of Her-2 associated with cancer
7) Confidence 0.04 Published 2004 Journal J Transl Med Section Body Doc Link PMC441417 Disease Relevance 0.48 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox